Get the Stockscreener App
53.42
4.11%
2.11
Palvella Therapeutics Inc stock is traded at $53.42, with a volume of 161.87K.
It is up +4.11% in the last 24 hours and up +48.39% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$51.31
Open:
$51.72
24h Volume:
161.87K
Relative Volume:
1.24
Market Cap:
$590.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+12.94%
1M Performance:
+48.39%
6M Performance:
+177.94%
1Y Performance:
+0.00%
1-Day Range:
$50.94
$53.93
1-Week Range:
$46.08
$53.93
52-Week Range:
$11.17
$53.93
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
125 STRAFFORD AVE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
53.42 | 547.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Palvella Therapeutics Inc. Breaks Losing Streak — Is the Trend Reversing2025 Technical Patterns & High Conviction Investment Ideas - beatles.ru
Palvella Therapeutics Inc. stock trend forecastJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
Will Palvella Therapeutics Inc. benefit from macro trends2025 Price Action Summary & Free Technical Pattern Based Buy Signals - Newser
Is Palvella Therapeutics Inc. in Accumulation Phase NowMarket Risk Summary & Growth Focused Entry Point Reports - classian.co.kr
Technical Heatmap Flags Palvella Therapeutics Inc. for WatchWeekly Risk Summary & Technical Buy Zone Confirmations - beatles.ru
Using flow based indicators on Palvella Therapeutics Inc.Market Weekly Review & AI Driven Price Predictions - Newser
Palvella Therapeutics Inc. stock momentum explainedPortfolio Performance Report & AI Forecast Swing Trade Picks - Newser
Canaccord Genuity raises Palvella Therapeutics stock price target on strong trial enrollment - Investing.com Canada
Live market analysis of Palvella Therapeutics Inc.Market Activity Summary & Free High Return Stock Watch Alerts - Newser
How hedge fund analytics apply to Palvella Therapeutics Inc. stockEarnings Growth Summary & Consistent Return Strategy Ideas - Newser
Applying Elliott Wave Theory to Palvella Therapeutics Inc.Volume Spike & Proven Capital Preservation Methods - Newser
Will Palvella Therapeutics Inc. stock split in the near futureWeekly Profit Report & Detailed Earnings Play Strategies - Newser
How to track smart money flows in Palvella Therapeutics Inc.July 2025 Opening Moves & Stock Market Timing Techniques - Newser
Will Palvella Therapeutics Inc. stock recover after recent drop2025 Price Action Summary & Weekly High Return Forecasts - Newser
Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsJuly 2025 Big Picture & Growth Focused Stock Reports - Newser
HC Wainwright Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock - Defense World
Palvella Therapeutics Inc. stock volume spike explainedJuly 2025 Spike Watch & Precise Swing Trade Entry Alerts - Newser
HC Wainwright Boosts Palvella Therapeutics (NASDAQ:PVLA) Price Target to $75.00 - Defense World
Is Palvella Therapeutics Inc. forming a reversal patternEarnings Miss & Risk Managed Trade Strategies - Newser
Chardan Capital Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Given a $75.00 Price Target by HC Wainwright Analysts - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Given New $75.00 Price Target at HC Wainwright - Defense World
Is Palvella Therapeutics Inc. stock entering bullish territoryPortfolio Update Report & Weekly Hot Stock Watchlists - Newser
Detecting price anomalies in Palvella Therapeutics Inc. with AIEarnings Risk Summary & Detailed Earnings Play Alerts - Newser
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating - 富途牛牛
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright - MSN
What institutional flow reveals about Palvella Therapeutics Inc.Earnings Summary Report & AI Enhanced Trading Alerts - Newser
Exit strategy if you’re trapped in Palvella Therapeutics Inc.Index Update & Safe Entry Zone Tips - Newser
What makes Palvella Therapeutics Inc. stock price move sharplyWeekly Trend Report & Low Drawdown Momentum Ideas - Newser
Palvella Completes Enrollment in Phase 3 SELVA Trial - MSN
What indicators show strength in Palvella Therapeutics Inc.Trade Ideas & Low Risk Investment Opportunities - Newser
How to read the order book for Palvella Therapeutics Inc.July 2025 Selloffs & Weekly Momentum Picks - Newser
Ranking Palvella Therapeutics Inc. among high performing stocks via toolsMarket Activity Recap & Accurate Technical Buy Alerts - Newser
Visual trend scoring systems applied to Palvella Therapeutics Inc.Portfolio Value Summary & Short-Term Swing Trade Alerts - Newser
Palvella:HC Wainwright Raises Buy Rating, PT to $75 from $38 - AInvest
Palvella Therapeutics: Q2 Earnings Snapshot - Norwalk Hour
Risk vs reward if holding onto Palvella Therapeutics Inc.Weekly Profit Report & Low Drawdown Investment Ideas - Newser
Palvella Therapeutics Advances Rare Disease Pipeline - TipRanks
Palvella Posts Cash Gain and Trial Wins - AOL.com
Palvella Therapeutics price target raised to $60 from $50 at Chardan - TipRanks
Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target - TipRanks
Palvella Therapeutics price target raised to $60 from $45 at Stifel - MSN
Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential - TipRanks
Palvella Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Earnings call transcript: Palvella Therapeutics Q2 2025 shows stock decline - Investing.com
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Palvella Therapeutics Inc Stock (PVLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JENKINS GEORGE M | Director |
Apr 09 '25 |
Buy |
20.13 |
2,500 |
50,325 |
183,171 |
| JENKINS GEORGE M | Director |
Dec 18 '24 |
Buy |
12.93 |
4,000 |
51,720 |
180,671 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):